These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 10348466

  • 1. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
    Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP.
    Mov Disord; 1999 May; 14(3):436-42. PubMed ID: 10348466
    [Abstract] [Full Text] [Related]

  • 2. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
    Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, Turk MF, Burnett OL.
    Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
    [Abstract] [Full Text] [Related]

  • 3. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group.
    JAMA; 2002 Apr 03; 287(13):1653-61. PubMed ID: 11926889
    [Abstract] [Full Text] [Related]

  • 4. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB.
    Ann Neurol; 1998 Jun 03; 43(6):792-800. PubMed ID: 9629849
    [Abstract] [Full Text] [Related]

  • 5. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.
    J Nucl Med; 1998 Sep 03; 39(9):1500-8. PubMed ID: 9744331
    [Abstract] [Full Text] [Related]

  • 6. Levodopa and the progression of Parkinson's disease.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group.
    N Engl J Med; 2004 Dec 09; 351(24):2498-508. PubMed ID: 15590952
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M, Kim YJ, Erami SS, Ballinger JR, Vines D, Tanaka F, Lang AE.
    J Nucl Med; 1999 Apr 09; 40(4):530-8. PubMed ID: 10210210
    [Abstract] [Full Text] [Related]

  • 9. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
    Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S.
    Proc Natl Acad Sci U S A; 1993 Dec 15; 90(24):11965-9. PubMed ID: 8265656
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG, Müller TT, Zander C, Kuhn W, Farahati J, Reiners C, Coenen HH.
    J Investig Med; 1997 Oct 15; 45(8):448-52. PubMed ID: 9394097
    [Abstract] [Full Text] [Related]

  • 12. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y.
    J Nucl Med; 2004 Oct 15; 45(10):1688-93. PubMed ID: 15471834
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.
    Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G.
    Eur J Nucl Med; 1997 Mar 15; 24(3):320-5. PubMed ID: 9143472
    [Abstract] [Full Text] [Related]

  • 15. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.
    Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, Zea-Ponce Y, Neumeyer JL, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Feb 15; 37(2):222-8. PubMed ID: 8667048
    [Abstract] [Full Text] [Related]

  • 16. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, Janssen AG, Stoof JC, van Royen EA.
    J Nucl Med; 1998 Nov 15; 39(11):1879-84. PubMed ID: 9829575
    [Abstract] [Full Text] [Related]

  • 17. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.
    Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL.
    Synapse; 1993 Apr 15; 13(4):295-309. PubMed ID: 7683143
    [Abstract] [Full Text] [Related]

  • 18. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE, Lee WY, Choe YS, Kim JH.
    Neurol Res; 1999 Apr 15; 21(3):255-61. PubMed ID: 10319333
    [Abstract] [Full Text] [Related]

  • 19. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease.
    Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, Dondi M, Fanti S, Pettinato C, Baruzzi A.
    Clin Neuropharmacol; 2004 Apr 15; 27(3):111-5. PubMed ID: 15190232
    [Abstract] [Full Text] [Related]

  • 20. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, Lee MC.
    J Neurol Neurosurg Psychiatry; 1998 Jul 15; 65(1):60-4. PubMed ID: 9667562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.